小分子降解模仿剂用于向蛋白质降解
1Department of Medicinal Chemistry, College of Pharmacy, University of Florida, FL32610, U.S.A.
Essays in biochemistry
|October 22, 2025
概括
向蛋白质降解利用小分子降解模仿剂来选择性地降解引起疾病的蛋白质. 这种方法利用无素-蛋白酶体系统获得治疗效益.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- 无素-蛋白酶体系统通过无素化降解超过80%的细胞内蛋白质.
- 对于基质特异性而言,E3无素连接酶至关重要,它识别了决定蛋白质半衰期的降解动机.
- 向蛋白质降解是一种新的治疗策略.
研究的目的:
- 对针对蛋白质降解的小分子降解模仿剂进行审查.
- 突出利用蛋白质降解途径用于疾病治疗的机制.
主要方法:
- 关于小分子降解模拟剂的文献综述.
- 对泛素-蛋白酶系统和E3结合酶功能的分析.
- 讨论为蛋白质稳定或降解引入人工降解物.
主要成果:
- 小分子降解模仿剂提供了一种诱导特定蛋白质降解的策略.
- 降解子的可获得性会影响蛋白质的稳定性和降解率.
- 这种方法在药物发现中具有潜力,用于向与疾病相关的蛋白质.
结论:
- 小分子降解模仿剂是针对蛋白质降解的有希望的工具.
- 利用无素-蛋白酶体系统提供了新的治疗途径.
- 这些模仿剂的进一步开发可能会导致各种疾病的新治疗方法.
相关概念视频
Regulated Protein Degradation
8.7K
It is vital to regulate the activity of enzymatic as well as non-enzymatic proteins inside the cell. This can be achieved either through creating a balance between their rate of synthesis and degradation or regulating the intrinsic activity of the protein. Both these regulation mechanisms play an essential role in the normal functioning of cells.
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
8.7K
Regulated Protein Degradation
3.1K
3.1K
GPCR Desensitization
7.9K
G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...
7.9K
Export of Misfolded Proteins out of the ER
5.0K
After folding, the ER assesses the quality of secretory and membrane proteins. The correctly folded proteins are cleared by the calnexin cycle for transport to their final destination, while misfolded proteins are held back in the ER lumen. The ER chaperones attempt to unfold and refold the misfolded proteins but sometimes fail to achieve the correct native conformation. Such terminally misfolded proteins are then exported to the cytosol by ER-associated degradation or ERAD pathway for...
5.0K
Targets for Drug Action: Overview
10.0K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
10.0K
The Proteasome
10.1K
Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
10.1K


